First-Ever Clinical Trial Demonstrates Safety, Molecular Readout and Promise of Pre- and Post-Surgery Immunotherapy Combination for Patients With Operable Mesothelioma
September 09, 2025
September 09, 2025
BALTIMORE, Maryland, Sept. 9 (TNSjou) -- Johns Hopkins Medicine issued the following news release:
* * *
First-Ever Clinical Trial Demonstrates Safety, Molecular Readout and Promise of Pre- and Post-Surgery Immunotherapy Combination for Patients with Operable Mesothelioma
A novel treatment approach using combination immunotherapy before and after surgery shows promise for patients with operable mesothelioma, according to a new study led by investigators at . . .
* * *
First-Ever Clinical Trial Demonstrates Safety, Molecular Readout and Promise of Pre- and Post-Surgery Immunotherapy Combination for Patients with Operable Mesothelioma
A novel treatment approach using combination immunotherapy before and after surgery shows promise for patients with operable mesothelioma, according to a new study led by investigators at . . .